Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an inflammatory neuropathy causing weakness and/or sensory symptoms and signs. Initial treatment consists of either intravenous immunoglobulin (IVIg) or corticosteroids. Currently, choice of treatment is based on patients’ and physician’s preference, as each treatment has his own specific advantages. IVIg works faster while corticosteroids lead to long-term remission.
Primary objectives of this double-blind randomized controlled trial is to explore whether combining IVIg and corticosteroids leads to more frequent long-term remission in CIDP compared to treatment with IVIg alone. Secondary objectives are to explore whether this leads to a higher rate of improvement and whether this combination reduces CIDP associated health care costs. Newly diagnosed patients will be treated by 3-weekly infusions with IVIg and placebo or IVIg and intravenous methylprednisolone during 4 months. Primary outcome is the number of patients in remission at 1 year after start of treatment.
The study will be conducted by the Dutch CIDP study group in collaboration with UK neuromuscular centers, the Dutch CIDP patient Group (Spierziekten Nederland) and Sanquin Plasma Products that will co-finance the study.
The results will be used to provide recommendations for induction treatment in CIDP which will be summarized in a national treatment guideline and future updates of the international CIDP guidelines.